Surgeon Erin Gillaspie, MD, said surgery still has a role in the treatment of mesothelioma while medical oncologist Hedy Kindler, MD, said newer systemic therapies make surgery obsolete in this space. Read more
Dr. Mark Kris, who leads the IASLC Pathologic Response Project, recently provided an update on efforts to collect data to confirm whether pathologic complete response can predict long-term outcomes. Read more
Advocate Angus Pratt explores the issues patients face while researching their disease when inaccurate and out-of-date information is everywhere. Read more
The agency also granted approval to amivantamab as a treatment for patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations who progressed on or after platinum-based chemotherapy. Read more
Drs. Sara Ghandehari and Weijia Chua discuss how to best monitor patients when guidelines and protocols vary and more research is needed. Read more
Get to know IASLC’s new Chief Science Officer and learn more about the role she and her team will play in conquering thoracic cancers in the 21st century. Read more
The IASLC seeks the lung cancer community’s input to assess the use of molecular testing—and barriers to its implementation—worldwide. Read more
Drs. Umberto Malapelle, Jarushka Naidoo, Isabelle Opitz, and Noemí Reguart will lead WCLC when it returns to Barcelona September 6-9, 2025. Read more
Other recent regulatory moves include the FDA granting full approval to tepotinib for metastatic NSCLC harboring MET exon skipping alterations and new applications for amivantamab in the US and Europe. Read more
Artificial Intelligence in Thoracic Radiation Oncology: Treatment, Challenges, and Future Directions
+more
In part 2 of our look at AI’s impact on radiotherapy, Grace Lee, MD, Fridolin Haugg, MSc, and Raymond H. Mak, MD, discuss how AI may be leveraged when delivering radiotherapy, including improving our ability to predict treatment response and adverse events. Read more